Golden State Equity Partners Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Golden State Equity Partners boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,446 shares of the biopharmaceutical company’s stock after purchasing an additional 88 shares during the quarter. Golden State Equity Partners’ holdings in Regeneron Pharmaceuticals were worth $917,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of REGN. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. boosted its position in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 31 shares in the last quarter. OFI Invest Asset Management purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $28,000. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares in the last quarter. Finally, Tompkins Financial Corp purchased a new stake in Regeneron Pharmaceuticals during the first quarter worth $32,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on REGN. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $700.00 to $580.00 in a research report on Friday, May 30th. Citigroup reduced their target price on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating on the stock in a research report on Monday, June 2nd. UBS Group reduced their target price on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating on the stock in a research report on Thursday, June 5th. Bank of America dropped their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research note on Thursday, April 17th. Finally, Truist Financial dropped their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $822.58.

Regeneron Pharmaceuticals Stock Down 0.4%

REGN opened at $520.29 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The stock has a market cap of $56.17 billion, a P/E ratio of 13.25, a P/E/G ratio of 1.91 and a beta of 0.31. The stock’s 50 day moving average price is $555.86 and its 200 day moving average price is $636.54.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the prior year, the business earned $9.55 earnings per share. The firm’s revenue was down 3.7% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.68%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.